Manzanita Pharmaceuticals, Inc. was founded in May 2007 with the acquisition of intellectual property assets of Asilomar Pharmaceuticals, Inc. Manzanita is actively pursuing additional US, Canadian and European patent claims involving antiviral, analgesic and fluorescent probe conjugates. The company is headquartered in northern California (McKee), with team in San Diego (Webb), Edmonton (Campenot), Edinburgh (Dalziel) and Bethesda (Hill).